Compare CPNG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPNG | ALNY |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | 108000 | 115 |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3B | 38.4B |
| IPO Year | 2021 | 2004 |
| Metric | CPNG | ALNY |
|---|---|---|
| Price | $18.10 | $278.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 28 |
| Target Price | $32.00 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 25.0M | 987.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.50 | ★ 206.88 |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $34,534,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $13.15 | $52.67 |
| Revenue Next Year | $13.75 | $31.48 |
| P/E Ratio | ★ N/A | $119.66 |
| Revenue Growth | 14.09 | ★ 22.88 |
| 52 Week Low | $14.92 | $273.11 |
| 52 Week High | $34.08 | $495.55 |
| Indicator | CPNG | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 38.66 |
| Support Level | $17.81 | N/A |
| Resistance Level | $20.98 | $314.04 |
| Average True Range (ATR) | 0.92 | 10.34 |
| MACD | 0.40 | -1.29 |
| Stochastic Oscillator | 67.88 | 13.31 |
Coupang is South Korea's largest e-commerce platform that sells both owned and third-party inventory. Headquartered in the US, Coupang operates e-commerce businesses mainly in South Korea and Taiwan. The company has built an integrated logistics network that covers the entirety of South Korea, with extensive fulfillment centers that ensure timely delivery, even for orders placed seconds before midnight. Outside of its bread-and-butter e-commerce business, Coupang has expanded into Rocket delivery services to third-party merchants (fulfillment and logistics by Coupang), online grocery delivery Rocket Fresh, online meal delivery (Eats), e-commerce in Taiwan, luxury e-commerce (Farfetch), and travel.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.